Peter Allen

Overview:

I am a Surgical Oncologist with clinical and research training in pancreatic and hepatobiliary malignancy.  In 2018, I joined Duke University as the Chief of Surgical Oncology, and the Chief of Surgery in the Duke Cancer Institute.  Previously, I led the clinical and research efforts regarding pancreatic neoplasia within the Department of Surgery at Memorial Sloan Kettering Cancer Center, and served as the Associate Director for Clinical Programs within the David Rubenstein Center for Pancreatic Cancer Research. I also held the Murray F. Brennan endowed Chair in Surgery. 

Over the previous ten years, I have been interested in the progression of pancreatic precursor lesions called intraductal papillary mucinous neoplasms (IPMN).  These cystic precursor lesions of the pancreas present an opportunity for to both study cancer progression, and potentially prevent the development of this lethal malignancy.  My research has focused on biomarker development to identify high-risk IPMN as well as studies evaluating the cause of this disease process.  I have successfully completed phase II and phase III clinical trials in patients with pancreatic cancer and IPMN, and am currently the PI of a first-in-human multi-center randomized chemoprevention trial for pancreatic cancer that is targeting patients with high-risk IPMN.

My laboratory includes both pre and postdoctoral trainees, and they play a critical role in the development of our pancreatic cancer prevention program. 

Positions:

Professor of Surgery

Surgical Oncology
School of Medicine

David C. Sabiston, Jr. Distinguished Professor of Surgery

Surgical Oncology
School of Medicine

Chief, Division of Surgical Oncology

Surgical Oncology
School of Medicine

Health System Vice President for Cancer Services

Duke Cancer Institute
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.A. 1989

Harvard University

M.D. 1993

Dartmouth College, Geisel School of Medicine

Surgical Intern, Surgery

Walter Reed Army Medical Center

Surgical Resident, Surgery

Walter Reed Army Medical Center

Research Fellow

Memorial Sloan-Kettering Cancer Center

Surgical Oncology Fellow, Surgery

Memorial Sloan-Kettering Cancer Center

Grants:

Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas

Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

Administered By
Surgical Oncology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Detection and Prognosis of Early-stage Pancreatic Cancer by Interdependent Plasma Markers

Administered By
Surgical Oncology
Role
Principal Investigator
Start Date
End Date

Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Detection and Prognosis of Early-stage Pancreatic Cancer by Interdependent Plasma Markers

Administered By
Surgical Oncology
Awarded By
Van Andel Research Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers.

BACKGROUND: Resection remains the cornerstone of curative-intent treatment for biliary tract cancers (BTCs). However, recent randomized data also support a role for adjuvant chemotherapy (AC). This study aimed to characterize trends in the use of AC and subsequent outcomes in gallbladder cancer and cholangiocarcinoma (CCA). METHODS: The National Cancer Database (NCDB) was queried for patients with resected, localized BTC from 2010 to 2018. Trends in AC were compared among BTC subtypes and stages of disease. Multivariable logistic regression was used to identify factors associated with receipt of AC. Survival analysis was performed with Kaplan-Meier and multivariable Cox proportional hazards methods. RESULTS: The study identified 7039 patients: 4657 (66%) with gallbladder cancer, 1159 (17%) with intrahepatic CCA (iCCA), and 1223 (17%) with extrahepatic CCA (eCCA). Adjuvant chemotherapy was administered to 2172 (31%) patients, increasing from 23% in 2010 to 41% in 2018. Factors associated with AC included female sex, year of diagnosis, private insurance, care at an academic center, higher education, eCCA (vs iCCA), positive margins, and stage II or III disease (vs stage I). Alternatively, increasing age, higher comorbidity score, gallbladder cancer (vs iCCA), and farther travel distance for treatment were associated with reduced odds of AC. Overall, AC was not associated with a survival advantage. However, subgroup analysis showed that AC was associated with a significant reduction in mortality among patients with eCCA. CONCLUSIONS: Among the patients with resected BTC, those who received AC were in the minority. In the context of recent randomized data and evolving recommendations, emphasis on guideline concordance with a focus on at-risk populations may improve outcomes.
Authors
Rhodin, KE; Liu, A; Bartholomew, A; Kramer, R; Parameswaran, A; Uronis, H; Strickler, J; Hsu, D; Morse, MA; Shah, KN; Herbert, G; Zani, S; Nussbaum, DP; Allen, PJ; Lidsky, ME
MLA Citation
Rhodin, Kristen E., et al. “Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers.Ann Surg Oncol, vol. 30, no. 8, Aug. 2023, pp. 4813–21. Pubmed, doi:10.1245/s10434-023-13567-4.
URI
https://scholars.duke.edu/individual/pub1578203
PMID
37188803
Source
pubmed
Published In
Annals of Surgical Oncology
Volume
30
Published Date
Start Page
4813
End Page
4821
DOI
10.1245/s10434-023-13567-4

ASO Visual Abstract: Trends in Receipt of Adjuvant Chemotherapy and Impact on Survival in Resected Biliary Tract Cancers.

Authors
Rhodin, KE; Liu, A; Bartholomew, A; Kramer, R; Parameswaran, A; Uronis, H; Strickler, J; Hsu, D; Morse, MA; Shah, KN; Herbert, G; Zani, S; Nussbaum, DP; Allen, PJ; Lidsky, ME
MLA Citation
Rhodin, Kristen E., et al. “ASO Visual Abstract: Trends in Receipt of Adjuvant Chemotherapy and Impact on Survival in Resected Biliary Tract Cancers.Ann Surg Oncol, vol. 30, no. 8, Aug. 2023, pp. 4824–25. Pubmed, doi:10.1245/s10434-023-13637-7.
URI
https://scholars.duke.edu/individual/pub1578937
PMID
37183199
Source
pubmed
Published In
Annals of Surgical Oncology
Volume
30
Published Date
Start Page
4824
End Page
4825
DOI
10.1245/s10434-023-13637-7

Development, Deployment, and Implementation of a Machine Learning Surgical Case Length Prediction Model and Prospective Evaluation.

OBJECTIVE: Implement a machine learning model using only the restricted data available at case creation time to predict surgical case length for multiple services at different locations. BACKGROUND: The Operating Room (OR) is one of the most expensive resources in a health system, estimated to cost $22-133 per minute and generate about 40% of the hospital revenue. Accurate prediction of surgical case length is necessary for efficient scheduling and cost-effective utilization of the OR and other resources. METHODS: We introduced a similarity cascade to capture the complexity of cases and surgeon influence on the case length and incorporated that into a gradient boosting machine learning model. The model loss function was customized to improve the balance between over- and under-prediction of the case length. A production pipeline was created to seamlessly deploy and implement the model across our institution. RESULTS: The prospective analysis showed that the model output was gradually adopted by the schedulers and outperformed the scheduler-predicted case length in Aug-Dec 2022. In 33,815 surgical cases across outpatient and inpatient platforms, the operational implementation predicted 11.2% fewer under-predicted cases and 5.9% more cases within 20% of the actual case length compared with the schedulers and only over-predicted 5.3% more. The model assisted schedulers to predict 3.4% more cases within 20% of the actual case length and 4.3% fewer under-predicted cases. CONCLUSIONS: We created a unique framework that is being leveraged every day to predict surgical case length more accurately at case posting time and could be potentially utilized to deploy future machine learning models.
Authors
Zaribafzadeh, H; Webster, WL; Vail, CJ; Daigle, T; Kirk, AD; Allen, PJ; Henao, R; Buckland, DM
MLA Citation
Zaribafzadeh, Hamed, et al. “Development, Deployment, and Implementation of a Machine Learning Surgical Case Length Prediction Model and Prospective Evaluation.Ann Surg, June 2023. Pubmed, doi:10.1097/SLA.0000000000005936.
URI
https://scholars.duke.edu/individual/pub1582437
PMID
37264901
Source
pubmed
Published In
Ann Surg
Published Date
DOI
10.1097/SLA.0000000000005936

Hepatic artery infusion for unresectable colorectal cancer liver metastases: Palliation and conversion.

Patients with unresectable colorectal liver metastases are commonly treated with systemic chemotherapy to convert their disease to an operable state. Unfortunately, many patients remain unresectable after first-line chemotherapy and resort to second- and third-line regimens with poor results. Liver-directed strategies have historically been used in this setting. There has been a renewed interest in offering hepatic artery infusion chemotherapy combined with systemic chemotherapy to improve resectability or palliate disease. Prospective studies over the past 2 decades have produced encouraging data, even in chemorefractory patients. This therapy has expanded to multiple centers across North America and worldwide with similar results. This review addresses these data, specifically focusing on conversion to resection and palliation of colorectal liver metastases after patients have received multiple lines of systemic chemotherapy.
Authors
Zaidi, MY; Nussbaum, DP; Hsu, SD; Strickler, JH; Uronis, HE; Zani, S; Allen, PJ; Lidsky, ME
MLA Citation
Zaidi, Mohammad Y., et al. “Hepatic artery infusion for unresectable colorectal cancer liver metastases: Palliation and conversion.Surgery, May 2023. Pubmed, doi:10.1016/j.surg.2023.04.025.
URI
https://scholars.duke.edu/individual/pub1578423
PMID
37183130
Source
pubmed
Published In
Surgery
Published Date
DOI
10.1016/j.surg.2023.04.025

The global state of play: A study of the demographic characteristics of disability golfers.

BACKGROUND: Golf is a moderate-intensity physical activity that provides positive physical and mental health benefits. However, the inclusiveness of the sport for individuals with disabilities globally is unknown. OBJECTIVE: To characterize the demographics and disability characteristics of individuals engaging in disability golf globally. It was hypothesized that the majority of participants would be middle-aged, male, and from countries with higher gross domestic product, similar to the nondisabled population. DESIGN: Descriptive, cross-sectional analysis using European Disability Golf Association (EDGA) database. SETTING: Various international golf tournaments. PARTICIPANTS: Golfers (n = 1734) with disability from 44 countries registered with the EDGA (2017-2021). INTERVENTIONS: Not applicable. MAIN OUTCOMES: Descriptive analyses of frequencies, distributions, and means differences of demographic characteristics (age, gender, type of disability, level of handicap, golf cart use, and country of origin) of golfers with disability were performed. Data provided analysis of the association between number of participants and a country's gross domestic product (GDP). RESULTS: Individuals had a mean age of 52.5 (±15.6) years: 1589 (91.6%) male and 145 (8.4%) female. Twenty-three countries had female participation. The most commonly reported primary disability diagnoses were neurologic (24.8%), orthopedic (21.4%), and amputation below the knee (14.4%). Neurologic impairments (24.7%) were most common in men and orthopedic impairments (29.7%) were most common in women. Individuals with neurological impairments (27.4%) most frequently required golf carts to play. The GDP of a country had a positive correlation (r = 0.68) with the number of registered golfers with disability. CONCLUSION: Golf is played by individuals with a variety of disabilities and provides numerous benefits. However, there is an underrepresentation of youth, women, and individuals with certain impairments and from lower-income countries. These are the potential areas of opportunity to improve engagement and inclusiveness of golf.
Authors
Guillaume, S; Bennett, T; Allen, PM; Morrison, A; Hawkes, R; Jayabalan, P
MLA Citation
Guillaume, Stanley, et al. “The global state of play: A study of the demographic characteristics of disability golfers.Pm R, Feb. 2023. Pubmed, doi:10.1002/pmrj.12955.
URI
https://scholars.duke.edu/individual/pub1578714
PMID
36730163
Source
pubmed
Published In
Pm R
Published Date
DOI
10.1002/pmrj.12955